By Amechi Idumuebor, For Agenda Watchdog, May 5, 2020
(AGENDAWATCHDOG) – Pfizer has begun dosing Americans with its experimental coronavirus vaccines for its clinical trial in collaboration with BioNTech SE, the pharmaceutical giant announced Tuesday.
The US drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide US distribution by the end of the year, shaving several years off the typical vaccine development timeline.
The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000.
Pfizer joined the race to make a coronavirus vaccine late, but hopes that with its trial in 360 healthy volunteers, it can speed ahead and have more than 20 million doses ready by year-end – if the shot proves safe.